There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

Spain is investigating Novo Nordisk over concerns it may be indirectly marketing its weight loss drugs. Euronews Health spoke ...

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Explore Novo Nordisk's stock price predictions for 2025, 2026 and 2030, driven by the success of Ozempic and its expanding role in diabetes and obesity treatments. My Account Benzinga Edge ...

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...

Spain’s ministry of health has asked Novo Nordisk for clarification about a controversial obesity awareness campaign which may have broken the country’s law on promoting prescription drugs. The ...

The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk launches Wegovy, its anti-obesity drug, in India. Targeting a large obese population, Wegovy aims to improve ...